Pharmaceuticals & Therapeutics

Dartmouth Cancer Center gains a top designation for using GammaTile, an innovative implant that delivers immediate radiation during brain tumor surgery.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

Can-Fite BioPharma eyes key 2026 data readouts for its late-stage oral drugs targeting advanced liver cancer, psoriasis, and other unmet medical needs.

The world's largest bamboo resort opens in a Vietnamese heritage site, blending Hmong culture with advanced wellness for a new kind of regenerative travel.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

Viceroy Hotels isn't just hiring executives; it's assembling a team of specialists to redefine experiential luxury and accelerate its global expansion.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

A routine filing by hedge fund Balyasny Asset Management may have just put Avadel Pharmaceuticals in the M&A spotlight. Here's what the signal means.

A new tech platform is untangling the web of pharmacy sourcing for wellness clinics, promising to slash costs and administrative headaches. Is this the future?

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.